Platinum-based drugs: past, present and future Shahana DilrubaGanna V. Kalayda Review Article 17 February 2016 Pages: 1103 - 1124
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib Jeffrey C. BryanSrdan Verstovsek Review Article Open access 26 March 2016 Pages: 1125 - 1142
Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma Yoshihiro TanakaKazuhiro YoshidaTatsuhiko Miyazaki Original Article Open access 20 February 2016 Pages: 1143 - 1152
Erratum to: Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma Yoshihiro TanakaKazuhiro YoshidaTatsuhiko Miyazaki Erratum 25 April 2016 Pages: 1153 - 1155
A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors K. WatanabeS. OtsuY. Ando Original Article 12 April 2016 Pages: 1157 - 1164
The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer Meiko NishimuraMasanori ToyodaHironobu Minami Original Article Open access 21 April 2016 Pages: 1165 - 1170
Tanshinone I induces apoptosis and pro-survival autophagy in gastric cancers Xiaoping JingYichun XuLi He Original Article 21 April 2016 Pages: 1171 - 1181
A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy Fengying LiXinyou XieJun Zhang Original Article 21 April 2016 Pages: 1183 - 1191
Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma Jia LiHarriet KlugerMuhammad Wasif Saif Original Article 21 April 2016 Pages: 1193 - 1200
A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine Bart A.W. JacobsJelte MeulenaarSerena Marchetti Original Article 21 April 2016 Pages: 1201 - 1207
Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer Hironori FujiiHirotoshi IiharaYoshinori Itoh Original Article 22 April 2016 Pages: 1209 - 1215
YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo De CaiZhiqing QiuZhixiu Lin Original Article 23 April 2016 Pages: 1217 - 1229
Evaluation of artemisinins for the treatment of acute myeloid leukemia Christina D. DrenbergJassada BuaboonnamSharyn D. Baker Original Article 28 April 2016 Pages: 1231 - 1243
Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study Akimasa SekineHiroaki SatohTerufumi Kato Original Article 29 April 2016 Pages: 1245 - 1252
A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors Toshihiko DoiKohei ShitaraAtsushi Ohtsu Original Article 30 April 2016 Pages: 1253 - 1262
Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2 Aziz OuerdaniStéphane GoutagnyBenjamin Ribba Original Article 04 May 2016 Pages: 1263 - 1273
Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors Johanna C. BendellManish R. PatelHendrik-Tobias Arkenau Original Article Open access 05 May 2016 Pages: 1275 - 1283
Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis Xiaobing ShenJia WangYuchao Xu Original Article 06 May 2016 Pages: 1285 - 1302
A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques Melanie I. TitzeOtmar SchaafThorsten Lehr Original Article 09 May 2016 Pages: 1303 - 1314
Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma Goshi NishimuraTakahide TaguchiNobuhiko Oridate Clinical Trial Report 06 May 2016 Pages: 1315 - 1319
Erratum to: Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study Miriam KönigCornelia von HagensSerkan Sertel Erratum 19 April 2016 Pages: 1321 - 1321